Cancer neoantigens have attracted great interest in immunotherapy due to their ability to elicit antitumoral immune responses. These antigens are formed due to somatic mutations in the cancer genome that result in alterations of the original protein.
Introduction
Recent studies have demonstrated that T cells can recognize tumor-specific antigens that bound to the human leukocyte antigens (HLA) molecules at the surface of tumor cells (Efremova et al., 2017; Kato et al., 2018) . During tumor progression, accumulating somatic mutations in the tumor genome can affect protein-coding genes and result in mutated peptides (Efremova et al., 2017) . These mutated peptides, which are present in the malignant cells but not in the normal cells, may act as neoantigens and trigger T-cell responses due to the lack of thymic elimination of autoreactive T-cells (central tolerance) (Snyder et al., 2014; Bailey et al., 2016; . As result, these neoantigens appear to represent ideal targets attracting great interest for cancer immunotherapeutic strategies, including therapeutic vaccines and engineered T cells (Lu; Robbins, 2016; Efremova et al., 2017) .
In the last years, advances in next-generation sequencing have provided an accessible way to generate patient-specific data, which allows the prediction of tumor neoantigens in a rapid and comprehensive manner (Liu; Mardis, 2017) . Several approaches have been developed, such as pVAC-Seq (Hundal et al., 2016) , MuPeXI (Bjerregaard et al., 2017) , TIminer (Tappeiner et al., 2017) and TSNAD (Zhou et al., 2017) , which performs prediction of potential neoantigens produced by nonsynonymous mutations. However, none of these proposed tools considers tumor transcriptome sequencing data (RNA-seq) for identifying somatic mutations.
Moreover, only one of these tools provides quantification of the fraction of tumorinfiltrating immune cells types.
Here we are presenting a versatile tool with a graphical user interface (GUI), called neoANT-HILL, designed to identify potential neoantigens arising from cancer somatic missense mutations, frameshift and small indels. neoANT-HILL integrates several complementary features to prioritizing mutant peptides based on predicted binding affinity and mRNA expression level levels. We used datasets from GEUVADIS RNA sequencing project (Lappalainen et al., 2013) to demonstrate that RNA-seq is also a potential source of mutation detection. Finally, we applied our pipeline on a large melanoma cohort from The Cancer Genome Atlas (Weinstein et al., 2013) to demonstrate its utility in predicting and suggesting potential neoantigens.
Material and Methods

RNA-seq data processing
We obtained RNA-seq samples (n=15) from the GEUVADIS RNA sequencing project to identifying frameshift, indels and point mutations. Raw RNA-seq reads were mapped with STAR aligner (version 2.6.0) (Dobin, et al., 2013) in two-pass mapping protocol against the human reference genome version GRCh37. Mapped reads were processed according to GATK best practices (DePristo et al., 2011; Van der Auwera et al., 2013). Mutect2 (Cibulskis et al., 2013 ) was used to identifies frameshift, missense mutations and small indels. We limited our analysis to variants that presented a read depth (DP) >= 10 and were supported by at least five reads.
Our results were validated by comparing the corresponding genotype provided by 1000 Genomes Project Consortium (1KG) (1000 Genomes Project Consortium et al., 2015) . Bcftools isec was used to determine the intersection between the variant sets.
Melanoma dataset
We applied neoANT-HILL on a large melanoma cohort (SKCM, n = 466) obtained from The Genome Cancer Atlas (TCGA) to identifying potential neoantigens.
Expression levels (FPKM) from corresponding samples were also obtained. All missense mutations, frameshift and small indels were extracted. The mutant sequences were inferred and reported with its corresponding wild-type sequence.
Our analysis was limited to HLA class I molecules. We used a set of HLA molecules that were within the most frequent alleles collected in the 1KG Project, including HLA- NetMHC) provided by IEDB for lengths 8-, 9-, 10-and 11-mer. We selected mutant peptides which its matched normal peptide showed a predicted binding affinity >= 500 nM. We also consider only the mutant peptides with the lowest predicted IC50
per HLA allele to avoid overlapping candidates differing by the length.
Results
neoANT-HILL overview and availability
neoANT-HILL is a user-friendly integrated tool for the identification of potential neoantigens that could be used in personalized immunotherapy ( Figure 1 ). Our pipeline relies on VCF file (single-or multisample) or tumor transcriptome sequence data (RNA-seq) in which somatic mutation calling will be performed following GATK best practices with Mutect2. In the current implementation, neoANT-HILL supports VCF files generated using the human genome version GRCh37. Other human genome version must be converted to version GRCh37. A list of HLA alleles should also be provided. At first, the variants are properly annotated by snpEff (Cingolani et al., 2012) . The next step is identifying non-synonymous mutations (missense mutations, frameshift and indels) and infers the resulting mutant sequence. The 
Non-synonymous mutations identification on RNA-seq
We evaluate the utility of RNA-seq for identifying frameshift, indels and point mutations. We used samples from the GEUVADIS project since for those samples a reference genome was available through the 1K Genome project. Although these samples are not derived from tumor cells, the goal of these analysis was to benchmark the efficiency of our pipeline to detect somatic mutations from RNA-Seq data. Mutect2 was performed on tumor-only mode without distinction between somatic and germline variants. The overall called variants were then compared to the corresponding genotypes. We found that on average 72% of variants in coding regions detected by RNA-seq were confirmed by the genome sequencing (concordant calls) (Supplementary Table1). Variants in genes that are not expressed cannot be detected by RNA-seq. Mapping mismatches and RNA editing sites could partially explain discordant calls.
Predicted potential neoantigens on melanoma
We found approximately 198,000 records of predicted mutant peptides in the SKCM dataset from the TCGA project. It is important to note that the large amount of mutant peptides is due to the high mutational burden of melanoma and the set of HLA alleles that was used to run the binding prediction. Moreover, these mutant peptides were classified as strong (IC50 < 50 nM), intermediate (IC50 >= 50 nM and < 250 nM) and weak binder (IC50 >= 250 nM and < 500 nM) (Supplementary Table 2 ). We decided to focus on expressed mutant peptides classified as strong binders to further evaluation as potential neoantigens.
We observed that the distribution of the majority of strong binders mutant peptides are private and unique, which demonstrates the intratumor heterogeneity. However, we observed that frequent mutations may be likely to generate recurrent mutant peptides (Table 1) . For instance, a potential neoantigen (FSGEYIPTV), which was predicted to form a complex with HLA-A*02:01 allele, was found to be shared among 17 samples (3.65%). It was generated from the P29S mutation in gene RAC1.
Another mutation (P29L) in the same gene was also related to form a recurrent potential neoantigen (FLGEYIPTV) that was found in 5 samples (1.07%). As another example, we can also highlight another potential shared neoantigen (LSMIVLLPNK) related to mutation E250K in the SERPINB3 gene ( Figure 3B ). It was found in 6 samples (1.29%) and it was likely to form a complex with the HLA-A*11:01 allele. We also observed that overlapping sequences of different lengths have shown more stable binding to different alleles (Supplementary Table 3 ). For instance, the previous mentioned peptide FLGEYIPTV, related to P29L RAC1, was likely to strongly bind to HLA-A*02:01. While the decameter peptide FLGEYIPTVF, which is also related to the same mutation, have been show to respond to HLA-A*11:01 ( Figure 3A) .
Similarly, the peptide AQIEASLSV, from R414Q HHATL, have been shown to strongly respond to HLA-A*02:01, while LAQIEASLSV bound to HLA-A*15:01.
Discussion
Cancer immunotherapy is rapidly advancing due to the progress in the understanding We have also used melanoma dataset from TCGA to demonstrate the utility of neoANT-HILL in identifying potential neoantigens. We found several predicted patient specific and shared neoantigen candidates. The use of non-patient specific HLA alleles in this analysis may have generated false positive potential neoantigens. We observed that recurrent mutations in RAC1 and SERPINB3 genes are likely to form potential neoantigens. RAC1 P29S have been described as a candidate biomarker for treatment with anti-PD1 or anti-PD-L1 antibodies (Vu et al., 2015) . Mutations in SERPINB3 have also been related to response to immunotherapy ).
Therefore, our results suggests that screening these neoantigens can be used as predictive biomarkers for immune responses and potential targets for immunotherapies.
Our tool provides completely integrated analyses to predicting potential neoantigens candidates. neoANT-HILL is available through a user-friendly graphical interface which enables its usage by users without an advanced programming background.
However, neoANT-HILL still lacks some features that must be taken into consideration in future updates such as detection of mutations that arise from gene fusion, inference of HLA-class II and evaluation of similarity to known epitopes.
Software availability
neoANT-HILL is hosted publicly on GitHub at https://github.com/neoanthill/neoANT-HILL and the user documentation is also available on this page.
Data availability
The RNA-Seq dataset from Geuvadis RNA sequencing project were downloaded from the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) and this data can be accessed under the accession number E-GEUV-1. We used the individuals named NA12812, NA12749, NA20510, NA19119, NA19204, NA18498, NA12489, NA20752, NA18517, NA11992, NA19144, NA20759, NA19137, NA19257 and NA12006. The corresponding genotyping data (Phase I) were downloaded from the data portal of the 1KG Project (http://www.internationalgenome.org/). The melanoma TCGA mutation and expression data were obtained from cBIO portal by using the CGDS-R package.
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